Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vor Biopharma

< Previous 1 2 Next >
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Tickers VOR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.